-
EyePoint Pharmaceuticals Announces Positive Topline Results for DURAVYU in Wet AMD
NASDAQ: $EYPT A Major Milestone in Retinal Disease Treatment EyePoint Pharmaceuticals has officially announced the topline results from its LUCIA study, the second pivotal Phase 3 clinical trial evaluating the efficacy and safety of DURAVYU (vorolanib) for the treatment of wet age-related macular degeneration (wet AMD). Understanding the LUCIA Trial Results The LUCIA trial was…
-
EyePoint Pharmaceuticals Announces Positive Topline Results for Duravyu™ in Phase 3 LUGANO Trial
NASDAQ: $EYPT A Potential Breakthrough for Wet AMD EyePoint Pharmaceuticals has shared promising topline results from the LUGANO clinical trial, the first of two pivotal Phase 3 studies evaluating the efficacy and safety of Duravyu™ (EYP-1901). Designed as a potential treatment for wet age-related macular degeneration (wet AMD), this investigative therapy is being studied as…
-
Kodiak Sciences Advances Pipeline and Unveils New Clinical Data for KSI-101 in Uveitis Treatment
NASDAQ: $KOD Kodiak Sciences Inc. has announced significant progress in its clinical and scientific programs, with plans to present new data at the 2026 American Uveitis Society (AUS) Meeting and the Association for Research in Vision and Ophthalmology (ARVO) Meeting. These updates center on the clinical performance of KSI-101 in treating macular edema secondary to…